Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

A Previously Unknown Mutation in RABL3 Is Linked to Hereditary PDAC

DOI: 10.1158/2159-8290.CD-RW2019-130 Published October 2019
  • Article
  • Info & Metrics
Loading
  • Major Finding: A mutation in the little-studied gene RABL3 was found in a family with a history of PDAC.

  • Mechanism: RABL3 interacts with RAP1GDS1, which prenylates KRAS-4B, possibly causing RAS pathway dysfunction.

  • Impact: Further studies of RABL3 in hereditary cancers and RABL3–RAS pathway interactions are of interest.

Approximately 10% of cases of pancreatic ductal adenocarcinoma (PDAC) occur in people with a family history of the condition, but few causative mutations have been identified. Using whole-genome sequencing, Nissim and colleagues identified a rare nonsense mutation in RABL3, a gene about which little is known, in a family with a history of cancers, particularly PDAC. As would be expected of an oncogene, expression of the mutant RABL3 in a human cell line led to increased proliferation. Providing evidence for the role of the RABL3 mutation in cancer pathogenesis, zebrafish heterozygous for a truncated Rabl3 developed cancers at an accelerated rate after treatment with chemical carcinogens or on a Trp53-null background. Affinity purification-mass spectrometry using mutant and wild-type (WT) RABL3 uncovered several high-confidence interacting proteins, including Rap1 GTPase-GDP dissociation stimulator 1 (RAP1GDS1, also known as SmgGDS), a chaperone protein suspected to bind and prenylate small GTPases. Protein prenylation—the chemical linkage of hydrophobic molecules such as lipids to proteins—is required for the function of some proteins, including KRAS, and abnormal KRAS signaling is prevalent in PDAC. The mutant RABL3 increased the rate of prenylation of both WT KRAS-4B and an oncogenic mutant KRAS-4B, and a mouse cell line with all Kras alleles excised did not exhibit increased proliferation caused by the RABL3 mutation, implying that mutant RABL3's oncogenic effects may be KRAS-dependent. Further implicating the RAS pathway in the pathology caused by the RABL3 mutation, zebrafish homozygous for a truncated Rabl3 had a phenotype resembling that of some human RASopathies, including stunted growth, marked spinal deformities, dysmorphia of the craniofacial and rib bones with impaired bone mineralization, and signs of motor or neurologic abnormalities. Collectively, these results indicate that a germline mutation in RABL3 not previously known to be associated with cancer is robustly associated with cancer development, indicating that investigation of other mutations in this gene may be of interest. Further, the connection between RABL3 and the RAS pathway may also be worth studying.

Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, et al. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nat Genet 2019 Aug 12 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2019 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 9 (10)
October 2019
Volume 9, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Previously Unknown Mutation in RABL3 Is Linked to Hereditary PDAC
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Previously Unknown Mutation in RABL3 Is Linked to Hereditary PDAC
Cancer Discov October 1 2019 (9) (10) OF10; DOI: 10.1158/2159-8290.CD-RW2019-130

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Previously Unknown Mutation in RABL3 Is Linked to Hereditary PDAC
Cancer Discov October 1 2019 (9) (10) OF10; DOI: 10.1158/2159-8290.CD-RW2019-130
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Pancreatic Cancer

  • The Peptide Hormone Cholecystokinin Links Obesity to Pancreatic Cancer
  • Cysteine Is Required for Preventing Ferroptosis in Pancreatic Cancer
  • Neoantigens Elicit Protumorigenic Immune Responses in Pancreatic Cancer
Show more Pancreatic Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement